Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN)
Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN): A Randomized, Double-Blind, Placebo-Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dandan Zhang, PhD, MD
- Phone Number: +8618810532113
- Email: zx1zy@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute ischemic stroke patients within 7 days of onset
- 18 years of age or older, and gender not limited
- NIHSS score of 4 to 15
Exclusion Criteria:
- Secondary stroke caused by a tumor, traumatic brain injury, hematological disease, or other diseases with a confirmed diagnosis
- Pre-stroke mRS score of more than 1
- Known severe liver or kidney dysfunction
- Known allergies for ingredients in the investigational product
- Known bleeding diathesis or coagulation disorder
- Known medical condition likely to limit survival to less than 3 months
- Pregnant women (clinically evident) or breastfeeding women
- Participation in any investigational study in the previous 3 months
- Known dementia, uncontrolled psychiatric problems
- Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. The judgment is left to the discretion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: LongShengZhi capsule
Experimental group
|
LongShengZhi capsules, orally, 5 capsules each time, three times a day.
|
|
PLACEBO_COMPARATOR: LongShengZhi capsule placebo
Placebo group
|
LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of patients with excellent outcome
Time Frame: 90 days after randomization
|
Excellent outcome defined as a modified Rankin scale (mRS) score ≤ 1 (scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).
|
90 days after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distribution of the modified Rankin scale (mRS) scores
Time Frame: 30 days after randomization
|
Modified Rankin scale (mRS) scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death.
|
30 days after randomization
|
|
Distribution of the modified Rankin scale (mRS) scores
Time Frame: 90 days after randomization
|
Modified Rankin scale (mRS) scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death.
|
90 days after randomization
|
|
The proportion of patients with good outcome
Time Frame: 30 days after randomization
|
Good outcome defined as a modified Rankin scale (mRS) score ≤2(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).
|
30 days after randomization
|
|
The proportion of patients with good outcome
Time Frame: 90 days after randomization
|
Good outcome defined as a modified Rankin scale (mRS) score ≤2(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death).
|
90 days after randomization
|
|
Changes in National Institutes of Health Stroke Scale (NIHSS) scores
Time Frame: 90 days after randomization
|
Difference of NIHSS scores (range =0-42, with higher scores indicating more severe strokes) between baseline and 30 days after randomization or 90 days after randomization.
|
90 days after randomization
|
|
The proportion of patients with poor quality of life
Time Frame: 30 days after randomization
|
Poor quality of life defined as EuroQol Five Dimensions Questionnaire (EQ-D5) index score ≤0.5.
The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).
|
30 days after randomization
|
|
The proportion of patients with poor quality of life
Time Frame: 90 days after randomization
|
Poor quality of life defined as EuroQol Five Dimensions Questionnaire (EQ-D5) index score ≤0.5.
The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).
|
90 days after randomization
|
|
The proportion of patients with functional independence
Time Frame: 30 days after randomization
|
Functional independence measured withe BI, which was a commonly used scale for measuring the activity of daily living of people.
Score of 10-item scale ranges from 0 (worst) to 100 (best).
|
30 days after randomization
|
|
The proportion of patients with functional independence
Time Frame: 90 days after randomization
|
Functional independence measured withe BI, which was a commonly used scale for measuring the activity of daily living of people.
Score of 10-item scale ranges from 0 (worst) to 100 (best).
|
90 days after randomization
|
|
Changes in Motor function
Time Frame: 90 days after randomization
|
Motor function, measured by the Fugl-Meyer Motor Scale (FMMS) score(range from 0-100, with lower score showing worse motor status) change from baseline to 90 days after randomization.
|
90 days after randomization
|
|
Changes in Cognitive function
Time Frame: 90 days after randomization
|
Cognitive function, as measured using the Montreal Cognitive Assessment (MoCA) score (range from 0 to 30, with less than 26 indicating cognitive impairment) change from baseline to 90 days after randomization.
|
90 days after randomization
|
|
The proportion of adverse events (AEs)
Time Frame: 90 days after randomization
|
The proportion of AEs during the treatment.
|
90 days after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HX-DZM-202119
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.